牛平平,刘淑娟,陈小光,盛小刚,李 松.陈氏心衰方联合β-受体阻滞药治疗缺血性心肌病心衰疗效及对心功能、6 min步行试验影响[J].现代生物医学进展英文版,2022,(17):3275-3279. |
陈氏心衰方联合β-受体阻滞药治疗缺血性心肌病心衰疗效及对心功能、6 min步行试验影响 |
Efficacy of Chen's Xinshuai Recipe Combined with β-blockers in the Treatment of Ischemic Cardiomyopathy with Heart Failure and Its Effects on Cardiac Function and 6-min Walk Test |
Received:May 14, 2022 Revised:June 10, 2022 |
DOI:10.13241/j.cnki.pmb.2022.17.014 |
中文关键词: 陈氏心衰方 β-受体阻滞药 缺血性心肌病心衰 心功能 6 min步行试验 |
英文关键词: Chen's heart failure formula β-Receptor blockers Ischemic cardiomyopathy heart failure Cardiac function 6 min walking test |
基金项目:广东省中医药局科研项目(20201138) |
|
Hits: 670 |
Download times: 317 |
中文摘要: |
摘要 目的:探讨陈氏心衰方及β-受体阻滞药治疗缺血性心肌病心衰疗效及对心功能、6 min步行试验影响。方法:选取我院2022.4-2022.5所收治的70例缺血性心肌病心衰患者按照随机数字表法分为心衰方组和对照组,各35例,其中对照组采取常规治疗+β-受体阻滞药治疗,心衰方组对照组治疗基础上,加用陈氏心衰方治疗,对比两种治疗方案疗效及对心功能、6 min步行试验影响。结果:心衰方组的治疗有效率(97.1 %)显著高于对照组(82.9 %)(P<0.05);治疗后,两组心功能均显著改善,而与对照组相比,心衰方组LVEDD和LVESD显著降低,LVEF显著增加(P<0.05);治疗前6 min步行试验结果对比无统计学差异(P>0.05),治疗后两组患者6 min步行试验结果明显长于治疗前,且心衰方组治疗后也显著长于对照组(P<0.05);治疗前两组患者BNP水平、中医证候评分、生活质量评分差异无统计学意义(P>0.05),治疗后两组患者的BNP水平、中医证候评分、生活质量评分均明显降低,且心衰方组也显著低于对照组(P<0.05)。结论:陈氏心衰方及β-受体阻滞药治疗缺血性心肌病心衰疗效显著,可改善患者的心功能,疗效优于单一应用β-受体阻滞药,更适用于缺血性心肌病心衰的治疗,临床上积极及推广应用功能联合用药治疗方式。 |
英文摘要: |
ABSTRACT Objective: To explore Chen's heart failure formula and its application β- Effect of receptor blockers on heart failure in ischemic cardiomyopathy and its effect on cardiac function and 6-minute walk test. Methods: A total of 70 patients with ischemic cardiomyopathy and heart failure treated in our hospital from April 2022 to May 2022 were selected as the research objects, and were randomly divided into heart failure formula group and control group, with 35 patients in each group. The patients in the control group were treated with routine treatment+ β- The patients in the heart failure formula group were treated with Chen's heart failure formula on the basis of the treatment of the control group. The effects of the two treatment schemes on cardiac function and 6-minute walking test were compared. Results: The treatment effective rate of the heart failure formula group (97.1 %) was significantly higher than that of the control group (82.9 %) (P<0.05); After treatment, the cardiac function in both groups was significantly improved, while compared with the control group, the LVEDD and LVESD in the Xinshuaifang group were significantly decreased, and the LVEF was significantly increased (P<0.05); There was no statistical difference in the results of walking test 6 minutes before treatment (P>0.05). After treatment, the results of 6-min walking test in the two groups were significantly longer than those before treatment, and the heart failure formula group was also significantly longer than the control group after treatment (P<0.05); Before treatment, there was no significant difference in BNP level, TCM syndrome score and quality of life score between the two groups (P>0.05). After treatment, the BNP levels, TCM syndrome scores, and quality of life scores in the two groups were significantly decreased, and the heart failure formula group was also significantly lower than the control group (P<0.05). Conclusion: Chen's heart failure formula and β- Receptor blockers are effective in the treatment of ischemic cardiomyopathy with heart failure. They can improve the cardiac function of patients, and the curative effect is better than that of single application β- Receptor blockers are more suitable for the treatment of ischemic cardiomyopathy and heart failure. Clinically, functional combination therapy is actively and widely used. |
View Full Text
View/Add Comment Download reader |
Close |